|
MYCO-002
MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is said to be being developed towards the aim of improving the safety profile of MDMA. The drug is under development by Mydecine. It was patented in July 2021 and received breakthrough therapy designation from the Food and Drug Administration (FDA) in November 2021. As of November 2021, MYCO-002 is in the preclinical research for treatment of psychiatric disorders. The chemical structure of MYCO-002 does not yet appear to have been disclosed. See also * MYCO-006 * MYCO-007 * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... References Drugs with undisclosed chemical structures Entactogens Experimental entactoge ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Mydecine
Mydecine Innovations Group, or simply Mydecine, is an United States, American and Canada, Canadian pharmaceutical company that is developing psychedelic drug, psychedelics and entactogens as medicines. In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. However, the company was able to obtain more funding and did not shutdown. Mydecine made the first legal import of magic mushrooms into Canada in 2021. Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003), MYCO-004 (a transdermal patch, patch-delivered tryptamine), and MYCO-005 (a novel aza-, aza psilocin structural analog, analogue with putatively better drug safety, safety) and the novel MDMA-like entactogens MYCO-002 (putatively safer), MYCO-006 (short-acting), and MYCO-007 (short-acting). Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented (MY100) and (MY101) as short-acting ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Experimental Entactogens
This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.'' The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in October 2024. It is likely to become outdated with time. Under development Preregistration * Midomafetamine (MDMA ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MYCO-007
MYCO-007 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is a short-acting MDMA analogue. MYCO-007 is being developed by Mydecine. As of February 2024, it is in preclinical research. The chemical structure of MYCO-007 does not yet appear to have been disclosed. (MY100) and (MY101) were described in Mydecine's patent for short-acting MDMA analogues See also * MYCO-002 * MYCO-006 * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... References Drugs with undisclosed chemical structures Entactogens Experimental entactogens Monoamine releasing agents {{Psychoactive-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MYCO-006
MYCO-006 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is a short-acting and fast-onset MDMA analogue. Based on animal studies, it is predicted that MYCO-006 will have a duration of 1 to 2hours, about one-third the 6- to 8-hour duration of MDMA, and to onset 4times as fast as MDMA. MYCO-006 is being developed by Mydecine. As of February 2024, it is in preclinical research. The chemical structure of MYCO-006 does not yet appear to have been disclosed. and were described in Mydecine's patent for short-acting MDMA analogues. See also * MYCO-002 * MYCO-007 * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... References Drugs with undisclosed chemical structures Entac ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Preclinical Research
In drug development, preclinical development (also termed preclinical studies or nonclinical studies) is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug safety data are collected, typically in laboratory animals. The main goals of preclinical studies are to determine a starting, safe dose for first-in-human study and assess potential toxicity of the product, which typically include new medical devices, prescription drugs, and diagnostics. Companies use stylized statistics to illustrate the risks in preclinical research, such as that on average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug. Types Each class of product may undergo different types of preclinical research. For instance, drugs may undergo pharmacodynamics (what the drug does to the body) (PD), pharmacokinetics (what the body does to t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Entactogens
Entactogens, also known as empathogens or connectogens, are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, connectedness, emotional openness—that is, empathy—as particularly observed and reported for experiences with MDMA. This class of drug is distinguished from the classes of hallucinogens or psychedelics and stimulants, although entactogens, for instance MDMA, can also have these properties. Entactogens are used both as recreational drugs and are being investigated for medical use in the treatment of psychiatric disorders, for instance MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Notable members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, αMT, αET, and MDAI, among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its counte ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Drugs With Undisclosed Chemical Structures
A drug is any chemical substance other than a nutrient or an essential dietary ingredient, which, when administered to a living organism, produces a biological effect. Consumption of drugs can be via inhalation, injection, smoking, ingestion, absorption via a patch on the skin, suppository, or dissolution under the tongue. In pharmacology, a drug is a chemical substance, typically of known structure, which, when administered to a living organism, produces a biological effect. A pharmaceutical drug, also called a medication or medicine, is a chemical substance used to treat, cure, prevent, or diagnose a disease or to promote well-being. Traditionally drugs were obtained through extraction from medicinal plants, but more recently also by organic synthesis. Pharmaceutical drugs may be used for a limited duration, or on a regular basis for chronic disorders. Classification Pharmaceutical drugs are often classified into drug classes—groups of related drugs that have simila ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Chemical Structure
A chemical structure of a molecule is a spatial arrangement of its atoms and their chemical bonds. Its determination includes a chemist's specifying the molecular geometry and, when feasible and necessary, the electronic structure of the target molecule or other solid. Molecular geometry refers to the spatial arrangement of atoms in a molecule and the chemical bonds that hold the atoms together and can be represented using structural formulae and by molecular models; complete electronic structure descriptions include specifying the occupation of a molecule's molecular orbitals. Structure determination can be applied to a range of targets from very simple molecules (e.g., diatomic oxygen or nitrogen) to very complex ones (e.g., such as protein or DNA). Background Theories of chemical structure were first developed by August Kekulé, Archibald Scott Couper, and Aleksandr Butlerov, among others, from about 1858. These theories were first to state that chemical compounds are not a ran ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Entactogen
Entactogens, also known as empathogens or connectogens, are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, connectedness, emotional openness—that is, empathy—as particularly observed and reported for experiences with MDMA. This class of drug is distinguished from the classes of hallucinogens or psychedelics and stimulants, although entactogens, for instance MDMA, can also have these properties. Entactogens are used both as recreational drugs and are being investigated for medical use in the treatment of psychiatric disorders, for instance MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Notable members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, αMT, αET, and MDAI, among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its cou ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Breakthrough Therapy
Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review. Requirements A breakthrough therapy designation can be assigned to a drug if "it is a drug which is intended alone or in combination wit ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
